| scholarly article | Q13442814 |
| P50 | author | David Durantel | Q34333588 |
| P2093 | author name string | Fabien Zoulim | |
| C Trepo | |||
| C Vieux | |||
| E Khattab | |||
| E Sablon | |||
| I Ottevaere | |||
| I Vuillermoz | |||
| P433 | issue | 1 | |
| P921 | main subject | ribavirin | Q421862 |
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | 41-53 | |
| P577 | publication date | 2004-09-01 | |
| P1433 | published in | Journal of Medical Virology | Q15716684 |
| P1476 | title | Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy | |
| P478 | volume | 74 |
| Q46257659 | Establishment of a platform for molecular and immunological characterization of the RNA-dependent-RNA-polymerase NS5B of an Egyptian HCV isolate. |
| Q35293895 | Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy* |
| Q43033327 | Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C. |
| Q28546960 | Genetic Variability of Hepatitis C Virus (HCV) 5' Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin |
| Q27478102 | Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4 |
| Q36841724 | Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy |
| Q37425275 | HCV genetic variability: from quasispecies evolution to genotype classification |
| Q27486013 | Hepatitis C Virus Diversity and Evolution in the Full Open-Reading Frame during Antiviral Therapy |
| Q37247077 | Hepatitis C virus (HCV) employs multiple strategies to subvert the host innate antiviral response |
| Q37336496 | Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance |
| Q38224436 | Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview |
| Q27488410 | Influence of quasispecies on virological responses and disease severity in patients with chronic hepatitis C |
| Q43037304 | Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment sera |
| Q34225261 | Predictive factors for interferon and ribavirin combination therapy in patients with chronic hepatitis C |
| Q27481007 | Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy |
| Q59049605 | Ribavirin at the Era of Novel Direct Antiviral Agents for the Treatment of Hepatitis C Virus Infection: Relevance of Pharmacological Monitoring |
| Q91511684 | Ribavirin inhibition of cell-culture infectious hepatitis C genotype 1-3 viruses is strain-dependent |
| Q37724686 | Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children |
| Q42978970 | Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy |
| Q37597927 | Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. |
Search more.